Topotarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com

Copenhagen, Denmark - 13 April 2010 - Topotarget A/S (NASDAQ OMX: TOPO)
designates Professor Jean-Louis Misset as Chairman of its Medical and
Scientific Advisory Board. Jean-Louis Misset is a full professor of oncology at
the University and at the St. Louis Hospital Oncology Division in Paris,
France. Professor Misset is an experienced Key Opinion Leader within oncology
who has served as an advisor to several big Pharma Companies.

"I am very proud that Professor Jean-Louis Misset has accepted the position to
Chair Topotarget's Global Medical and Scientific Advisory Board. As I stated
earlier belinostat is a pipeline in a single molecule and has blockbuster
potential. Professor Misset will provide Topotarget with expert leadership to
help select the best clinical development path for belinostat and for the other
products in the pipeline,? said the CEO of Topotarget, Francois Martelet, MD.?
With the guidance of this Advisory Board we will drive our medical strategy
forward with the aim of full exploitation of belinostat's medical and
commercial potential?.

Professor Misset has a strong oncology background as an advisor in the field of
drug development. As a member of scientific boards and as an advisor Professor
Misset has experience of the clinical development of drugs including Topotecan
(SmithKlineBeecham), Docetaxel (Aventis), Alimta (Eli Lilly) and Herceptin
(Roche). Professor Misset will be building a board of highlevel senior drug
development people and key opinion leaders in their fields.

"I am very pleased to accept the assignment as Chairman of the Scientific
Advisory Board for belinostat. Belinostat has an interesting activity and
safety profile with the ability to combine with many active anti-cancer agents
both in hematological cancers and in solid tumors. The right strategy regarding
choice of indications, treatment schedules and doses are critical for the
success of belinostat, and I look forward to work with the Topotarget and
Spectrum teams?, said Professor Jean-Louis Misset.

Today's news does not change Topotarget's full-year financial guidance.

?

Topotarget A/S

For further information, please contact:

Francois Martelet Direct +45 39 17 94 99
CEO Mobil +45 31 36 83 41

Background information

About Topotarget
Topotarget (NASDAQ OMX: TOPO) is an international biotech company headquartered
in Denmark, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. Topotarget currently focuses, in collaboration with Spectrum
Pharmaceuticals, Inc., on the development in pivotal studies of its lead drug
candidate, Belinostat, which has shown proof of concept as monotherapy in
treating haematological malignancies and positive results in solid tumours.
Belinostat can be used in combination with full doses of chemotherapy, and is
in a pivotal trial within PTCL (peripheral T-cell lymphoma). Topotarget is
directing its efforts on belinostat and on additional key cancer targets,
including HDACi, NAD+, mTOR, FASLigand and topoisomerase II inhibitors. The
Company's first marketed product, Savene®/Totect®, was approved by EMEA in 2006
and the FDA in 2007, and is marketed by Topotarget's own sales force in the US.
For more information, please refer to www.topotarget.com.

Topotarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; Topotarget's history of
incurring losses and the uncertainty of achieving profitability; Topotarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against Topotarget's products, processes and
technologies; the ability to protect Topotarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.

announcement no 13-10 topotarget designates professor jean-louis misset as chairman of its global medical and scientific advisory board.pdf